Project Grant HT94252410584
Award Date 7/1/24
Completion Date 6/30/27
Dollars Obligated $779K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New Orleans, LA 70118, USA
Similar Awards
- This $188,403 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is funding the University of California, Los Angeles (UCLA) to develop new cell-mediated immunotherapeutic strategies for small-cell lung cancer. The award period runs from January 1, 2025 to December 31, 2025. Through this funding, UCLA will conduct advanced biomedical research to transform healthcare for military service members, veterans, and the...
- The Department of the Army Medical Command awarded Duke University a $547,664 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from June 2021 to May 2023 to exploit targeted therapy-induced ATM dependence in residual lung tumors. Through this award, Duke University researchers will investigate medical solutions for the battlefield by transforming health care for Service Members and the American public through innovative and...
- The Defense Health Agency awarded a $168,200 Project Grant to Health Research, Inc. Roswell Park Division under the Military Medical Research and Development program (CFDA 12.420) to investigate alternative polyadenylation as a mediator of therapeutic resistance in lung cancer. The two-year award beginning July 1, 2021 will support research into innovative medical solutions for lung cancer treatment through the study of alternative polyadenylation, a novel area of investigation that could help...
- This $819,841 federal Project Grant awarded by the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), supports Duke University's research to pharmacologically activate a newly discovered KEAP1-ATF4-CHOP axis in order to select against targeted therapy resistance in non-small cell lung cancer (NSCLC). The research project aims to develop new treatments that can overcome resistance to existing targeted therapies for NSCLC. Duke University, through its...
- The Trustees of the University of Pennsylvania will receive $975,000 through a three-year Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will support lung cancer research from July 1, 2023 to June 30, 2026. Through this funding, the University and its Clinical Practices will conduct biomedical research to transform service member healthcare and investigate medical solutions applicable to battlefield medicine....
- The federal Project Grant award, titled "DECIPHERING EPIGENETIC MECHANISMS THAT DICTATE POOR RESPONSES TO KRAS INHIBITION IN LUNG CANCER," was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The $610,656 award, granted on March 1, 2025, supports biomedical research at The Trustees of Columbia University in the City of New York to investigate epigenetic factors that contribute to lung cancer patients' poor responses to...
- This $828,591 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by Duke University to target the tumor microenvironment and enhance immunotherapy for small cell lung cancer (SCLC). The award period runs from May 1, 2025 to April 30, 2027. As a leading private research institution, Duke University's Office of Research Administration will leverage its multidisciplinary scientific expertise to advance medical...
- This $762,992 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the University of Texas MD Anderson Cancer Center to map and predict therapy resistance in small cell lung cancer (SCLC) using liquid biopsies. The 3-year award, effective July 1, 2024, will enable MD Anderson to conduct personalized analyses to better understand how SCLC tumors evolve and become resistant to treatment. This work aims to...
- This federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $859,773 to Yale University to conduct research on biomarkers and targets of leptomeningeal disease progression from non-small cell lung cancer (NSCLC) brain metastasis. The research aims to transform healthcare for military service members, veterans, and the public by developing innovative diagnostic tools and therapeutic interventions for this critical...
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $872,914 to Tulane University to conduct research on "Mast Cell Activation as a Mediator of Persistent Neurological Symptoms Partly Mediated Through a Novel Matrix Metalloproteinase." The award period runs from September 1, 2024 to August 31, 2027. The Military Medical Research and Development program supports a broad range of biomedical research...